Robert J. Cardnell

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Milena Perez Mak, Pan Tong, Lixia Diao et al. · Clinical Cancer Research · 2015 · 581 citations · Full text

Medicine, Cancer Biology, Oncology +17

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

M. Catherine Pietanza, Saiama N. Waqar, Lee M. Krug et al. · Journal of Clinical Oncology · 2018 · 398 citations · Full text

Medicine, Oncology, Pharmacology +13

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype

Carminia Maria Della Corte, Triparna Sen, Carl M. Gay et al. · Journal of Thoracic Oncology · 2020 · 204 citations · Full text

Life Sciences, Immunology, Molecular Biology +12

Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

Robert J. Cardnell, Ying Feng, Lixia Diao et al. · Clinical Cancer Research · 2013 · 180 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer

Kasey R. Cargill, C. Allison Stewart, Elizabeth M. Park et al. · Cancer & Metabolism · 2021 · 64 citations · Full text

Life Sciences, Biochemistry, Oncology +17